Azenta to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 22, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Azenta, Inc. (Nasdaq: AZTA) announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 22, 2022. The event will feature a presentation at 3:00 PM ET in a virtual format, accessible via Azenta's investor relations website.
Azenta specializes in life sciences solutions, offering cold-chain sample management and genomic services for drug development and clinical research. The company rebranded from Brooks Automation, Inc. on December 1.
Details
News Market Reaction – AZTA
The recorded move for AZTA in the trading session of this news was -3.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHELMSFORD, Mass., March 11, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 22, 2022, which includes a presentation beginning at 3:00pm ET. The conference will be held in a virtual environment. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December 1st, the company changed its name and ticker to Azenta, Inc. (Nasdaq: AZTA) from Brooks Automation, Inc, (Nasdaq: BRKS).
Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
INVESTOR CONTACTS:
Sara Silverman
Director, Investor Relations
Azenta Life Sciences
978.262.2635
sara.silverman@azenta.com
Sherry Dinsmore
Azenta Life Sciences
978.262.2400
sherry.dinsmore@azenta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-to-participate-in-the-keybanc-capital-markets-life-sciences--medtech-investor-forum-301500722.html
SOURCE Azenta
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.